Expanded coverage under a Medicare-Medicaid partnership to treat all prevalent cases of hepatitis C appears to be cost-effective by saving money and improving patient outcomes.
William V. Padula, PhD
Advertisement
Articles by William V. Padula, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%
3
FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies
4
Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access
5